METHOD FOR EVALUATION OF THROMBOCYTE AGGREGATION Russian patent published in 2010 - IPC G01N33/86 

FIELD: medicine.

SUBSTANCE: invention can be used to evaluate thrombocyte aggregation in the intravascular-related conditions to diagnose thrombocyte hypo- and hyperaggregation in physiological and pathological statuses. A blood sample is drawn, stabilised with 3.8% sodium citrate, divided into plasma and erythrocytes by centrifugation. That is followed with the thrombocyte aggregation test with simultaneously addition of at least three aggregation inducers chosen of the group including ADP, adrenaline, collagen, thrombin. The time of aggregate generation while adding the aggregation inducers is recorded with calculating the average aggregation within a damage area (AADA). If the AADA is 20.0-23.75 sec, the thrombocyte aggregation is considered to be normal. The AADA 12.1-19.9 sec indicates the risk of hyperaggregation; while the value 12.0 sec and less indicates high thrombocyte aggregation with potential thromboses in the nearest future. If the AADA is 23.76-29.9, there is a risk of hypoaggregation; the values 30.0 sec and higher show hypoaggregation with developing hemorrhagic diathesis in the nearest future.

EFFECT: application of the method allows diagnosing thrombocyte hypo- and hyperaggregation in small plasma amount.

3 dwg, 3 tbl, 4 ex